PubMed ID: 27752844
Author(s): Levin LA. Translational pharmacology in glaucoma neuroprotection. Handb Exp Pharmacol. 2017;242:209-230. doi: 10.1007/164_2016_20. PMID 27752844
Journal: Handbook Of Experimental Pharmacology, Volume 242, 2017
Glaucoma is both the most common optic neuropathy worldwide and the most common cause of irreversible blindness in the world. The only proven treatment for glaucomatous optic neuropathy is lowering the intraocular pressure, achieved with a variety of pharmacological, laser, and surgical approaches. Over the past 2 decades there has been much basic and clinical research into achieving treatment of the underlying optic nerve damage with neuroprotective approaches. However, none has resulted in regulatory approval based on successful phase 3 studies. This chapter discusses the reasons for this “lost in translation” aspect of glaucoma neuroprotection, and outlines issues at the laboratory and clinical trial level that need to be addressed for successful development of neuroprotective therapies.